Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2

PURPOSE: COPD exacerbations are associated with worsening clinical outcomes and increased healthcare costs, despite use of optimal medical therapy. A novel bronchoscopic therapy, targeted lung denervation (TLD), which disrupts parasympathetic pulmonary innervation of the lung, has been developed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Valipour, Arschang, Shah, Pallav L, Herth, Felix J, Pison, Christophe, Schumann, Christian, Hübner, Ralf-Harto, Bonta, Peter I, Kessler, Romain, Gesierich, Wolfgang, Darwiche, Kaid, Lamprecht, Bernd, Perez, Thierry, Skowasch, Dirk, Deslee, Gaetan, Marceau, Armelle, Sciurba, Frank C, Gosens, Reinoud, Hartman, Jorine E, Conway, Francesca, Duller, Marina, Mayse, Martin, Norman, Holly S, Slebos, Dirk-Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652218/
https://www.ncbi.nlm.nih.gov/pubmed/33177818
http://dx.doi.org/10.2147/COPD.S267409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652218/
https://www.ncbi.nlm.nih.gov/pubmed/33177818
http://dx.doi.org/10.2147/COPD.S267409

Ejemplares similares